Arkolith/Insider Trading/SYRS/Form 4

Roth David

Chief Medical OfficerSyros Pharmaceuticals, Inc. (SYRS) · full profile →Form 4 · filed Apr 2, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$747
Net Open-Market Flow
-$747
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 2, 2024Sell(S)150$4.98$74710K
Apr 1, 2024Tax withholding(F)5K$5.12$24K11K
Mar 31, 2024Option exercise(M)13K——15K
Mar 31, 2024Option exercise(M)2K——2K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 31, 2024Option exercise(M)2K—$04K
Mar 31, 2024Option exercise(M)13K—$027K

Transaction Codes

S
Open-market sale
F
Shares withheld for taxes
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-040302) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML